IP Library Granted Patent US 8,008,013
Granted Patent B2
US 8,008,013 · App. 12/272,265 · Granted Aug 30, 2011

Predicting and diagnosing patients with autoimmune disease

Assignee: Oklahoma Medical Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,008,013
App. No.
12/272,265
Granted
Aug 30, 2011
Kind
B2
Abstract

The present invention provides methods for the prediction and diagnosis of autoimmune diseases, including Systemic Lupus Erythematosus, using single nucleotide polymorphism in TNFAIP3 (A20).

Claims (15)

1. A method of identifying an increased risk of developing systemic lupus erythematosus (SLE) in a human subject comprising:

(a) obtaining a nucleic acid-containing sample from said subject;

(b) determining the presence in the sample of an A allele at rs7749323 in a tumor necrosis factor, alpha-induced protein 3 (TNFAIP3) gene, wherein the presence of the A allele at rs7749323 indicates an increased risk for SLE in the subject.

2. The method of claim 1 further comprising determining the presence or absence of an allele at rs10499197, rs3757173, rs629953, rs5029939, rs2230926 or combination thereof.

3. The method of claim 1 further comprising determining the presence or absence of an allele at rs10499197, rs3757173, rs629953, rs5029939, and rs2230926.

4. The method of claim 1 , further comprising treating said subject based on the results of step (b).

5. The method of claim 1 , further comprising taking a clinical history from said subject.

6. The method of claim 1 , wherein determining comprises nucleic acid amplification.

7. The method of claim 6 , wherein amplification comprises PCR.

8. The method of claim 1 , wherein determining comprises primer extension.

9. The method of claim 1 , wherein determining comprises restriction digestion.

10. The method of claim 1 , wherein determining comprises sequencing.

11. The method of claim 1 , wherein determining comprises SNP specific oligonucleotide hybridization.

12. The method of claim 1 , wherein determining comprises a DNAse protection assay.

13. The method of claim 1 , wherein said sample is blood, sputum, saliva, mucosal scraping or tissue biopsy.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 14, 2017
From: OKLAHOMA MEDICAL RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042806/0821 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2009
From: GAFFNEY, PATRICK M.; MOSER, KATHY L.
To: OKLAHOMA MEDICAL RESEARCH FOUNDATION
Reel/Frame 022196/0296 →
Continuity (2)
Provisional Application 60988675 · Nov 16, 2007
Related Publication 20090130683A1 · May 21, 2009